• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Cephalon

Cephalon

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Global Nootropics Market Report 2017 - Forecast to 2024 with Regional Outlook, Growth Trends & Key Players - Research and Markets

    Global Nootropics Market Report 2017 - Forecast to 2024 with Regional Outlook, Growth Trends & Key Players - Research and Markets

  2. Why Retirement Funds Fall Short

    Cephalon CEPH announced Monday that Gabitril did not meet the primary endpoints in a Phase III study for generalized anxiety disorder (GAD). We're sticking with our fair value estimate of $44 per share, as we had assumed only a modest increase in Gabitril sales from this additional indication. ...

  3. Compelling Financial Benefit in Valeant's Latest Buy

    The proposed Salix acquisition boosts our fair value estimate significantly.

  4. Our Outlook for Health-Care Stocks

    While we remain bullish on the sector, health-care growth depends on the economy.

  5. Finding Good Pharma Stocks

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

©2017 Morningstar Advisor. All right reserved.